Navigation Links
UFE Highly Effective in Cases Where Focused Ultrasound to Treat Uterine Fibroids Failed

Significant Relief of Symptoms Noted From Uterine Fibroid Embolization

WASHINGTON, March 18 /PRNewswire-USNewswire/ -- Uterine fibroid embolization (UFE), a minimally invasive interventional radiology treatment for uterine fibroids, provides significant relief of symptoms for women whose focused ultrasound (FUS) treatment failed, according to a study released today during the Society of Interventional Radiology's 33rd Annual Scientific Meeting in Washington, D.C. Primary care physicians and gynecologists can feel confident in informing patients that a failed FUS treatment does not require subsequent gynecological surgery. Those women can be successfully treated with UFE. Patients with a single large fibroid are candidates for FUS; patients with many fibroids, which is more often the case, would be better treated with UFE. There is limited long-term follow-up data for FUS and limited information on fibroid recurrence rates. In this retrospective study from Boston's Brigham and Women's Hospital, seven post-FUS patients who experienced therapeutic failure and were subsequently re-treated with UFE were reviewed. In all patients, their symptoms -- such as heavy menstrual bleeding and the sensation of fullness or pressure in the lower abdomen -- improved.

"FUS is a newer procedure for uterine fibroids and whether it provides sustained symptom relief is still being evaluated. My research shows that when FUS fails, these women could benefit from uterine fibroid embolization," said Alisa Suzuki, M.D., interventional radiologist at Brigham and Women's Hospital.

Uterine fibroids are noncancerous (benign) growths that develop in the muscular wall of the uterus and are treated only if they are causing bothersome symptoms. With UFE, an interventional radiologist inserts a catheter into the femoral artery and using real-time imaging, guides the catheter up the artery and then releases tiny particles, the size of grains of sand, into the uterine arteries that supply blood to the fibroid tumor. This blocks the blood flow to the fibroid tumor and causes it to shrink and die. FUS focuses high-frequency, high-energy sound waves to generate heat at a specific point within the fibroid tissue to shrink the fibroid and relieve symptoms. FUS has been approved by the Food and Drug Administration (FDA) for several years. Due to the limited number of institutions providing FUS, the number of procedures performed is still limited.

"Today, women have more options. Fibroids will not kill a patient, but they could ruin her lifestyle. UFE is widely available; patients can easily obtain information about this interventional radiology treatment on the Internet. Women should ask for a consult with an interventional radiologist who can determine from MRI imaging whether they are candidates for either procedure. We have experience in treating fibroids, access to exciting new technologies and are happy to discuss various options with patients," said Suzuki.

Abstract 142, "When Sound Fails: Efficacy of Uterine Artery Embolization for Focused Ultrasound Surgery Therapeutic Failures," can be found at

About Uterine Fibroid Embolization

Uterine fibroids are very common noncancerous (benign) growths that develop in the muscular wall of the uterus. They can range in size from very tiny (a quarter of an inch) to larger than a cantaloupe. Occasionally, they can cause the uterus to grow to the size of a five-month pregnancy. In most cases, there is more than one fibroid in the uterus. Uterine fibroids can cause prolonged, heavy menstrual bleeding that can be severe enough to cause anemia or require transfusion, disabling pelvic pain and pressure, urinary frequency, pain during intercourse, miscarriage, interference with fertility and an abnormally large uterus--resembling pregnancy.

Twenty to 40 percent of women age 35 and older have uterine fibroids of a significant size. African American women are at a higher risk for fibroids: as many as 50 percent have fibroids of a significant size. Uterine fibroids are the most frequent indication for hysterectomy in premenopausal women and, therefore, are a major public health issue. Of the 600,000 hysterectomies performed annually in the United States, one-third are due to fibroids.

About the Society of Interventional Radiology

Interventional radiologists are physicians who specialize in minimally invasive, targeted treatments. They offer the most in-depth knowledge of the least invasive treatments available coupled with diagnostic and clinical experience across all specialties. They use X-ray, MRI and other imaging to advance a catheter in the body, usually in an artery, to treat at the source of the disease internally. As the inventors of angioplasty and the catheter-delivered stent, which were first used in the legs to treat peripheral arterial disease, interventional radiologists pioneered minimally invasive modern medicine.

Today many conditions that once required surgery can be treated less invasively by interventional radiologists. Interventional radiology treatments offer less risk, less pain and less recovery time compared to open surgery. Visit

Local interviews, medical illustrations and broadcast-quality video footage are available for UFE by contacting SIR's communications department at A UFE fact sheet and statistics can be found in the Media section at

SOURCE Society of Interventional Radiology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Consumer Specialty Products Association Highly Critical of NRDC Study on Home Air Fresheners
2. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
3. 18F-DG PET/CT can highly increase the detection of colorectal cancer
4. Plastic Surgery Complications and Deaths are Rare, Despite Highly Publicized Death of Donda West
5. CT angiography highly accurate, multicenter trials show
6. CT Angiography Highly Accurate: Multicenter Trials Show
7. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
8. Highly Promising Dutch Research Into Alzheimers Disease and Parkinsons Disease
9. Songbirds offer clues to highly practiced motor skills in humans
10. LASIK works well, according to long-term study of highly myopic patients
11. Researchers find less invasive, highly accurate methods
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology: